Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01585688 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01585688 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 13 participants.
The verdict
NCT01585688, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary objectives are to evaluate the safety and tolerability of hLL1-DOX, and to determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated dosing schedule). The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.
Interventions
- DRUG hLL1-DOX (IMMU-115)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-08 |
| Est. Completion | 2017-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01585688
The ClinicalTrials.gov registry entry for NCT01585688 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hLL1-DOX (IMMU-115) is the first listed.
NCT01585688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01585688 about?
NCT01585688 is a clinical study titled "Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL". The primary objectives are to evaluate the safety and tolerability of hLL1-DOX, and to determine the maximum tolerated dose (MTD) regimen (in terms of a dose and its associated dosing schedule). The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and i...
What is the current status of trial NCT01585688?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2012-08. Estimated completion is 2017-10.
What interventions are being tested in trial NCT01585688?
The interventions under investigation include: hLL1-DOX (IMMU-115) (DRUG).
Who is sponsoring clinical trial NCT01585688?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.